Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5N5
UPID:
N6MT1_HUMAN
Alternative names:
HemK methyltransferase family member 2; Lysine N-methyltransferase 9; Methylarsonite methyltransferase N6AMT1; Protein N(5)-glutamine methyltransferase
Alternative UPACC:
Q9Y5N5; B2RA97; Q96F73
Background:
Methyltransferase N6AMT1, known as HemK methyltransferase family member 2, Lysine N-methyltransferase 9, and Methylarsonite methyltransferase, plays a crucial role in protein methylation. It acts as a catalytic subunit in a heterodimer with TRMT112, targeting 'Lys-12' of histone H4 and a specific Glu residue in proteins, influencing cell cycle regulators and protein function. Additionally, it's involved in arsenic toxicity modulation through methylation processes.
Therapeutic significance:
Understanding the role of Methyltransferase N6AMT1 could open doors to potential therapeutic strategies.